Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

I-Ying Kuo1, You-En Yang1, Pei-Shan Yang1, Yu-Jou Tsai1, Hong-Tai Tzeng1, Hung-Chi Cheng2, Wan-Ting Kuo3, Wu-Chou Su4, Chih-Peng Chang5, Yi-Ching Wang1,3

1. Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
2. Department of Biochemistry, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
3. Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
4. Division of Oncology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
5. Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

**Background:** Increased IL-6 level, M2 macrophages and PD-1+CD8+ T cells in tumor microenvironments (TME) have been identified to correlate with resistance to checkpoint blockade immunotherapy, yet the mechanism remains poorly understood. Rab small GTPase-mediated trafficking of cytokines is critical in immuno-modulation. We have previously reported dysregulation of Rab37 in lung cancer cells, whereas the roles of Rab37 in tumor-infiltrating immune cells and cancer immunotherapy are unclear.

**Methods:** The tumor growth of the syngeneic mouse allograft in wild type or Rab37 knockout mice was analyzed. Imaging analyses and vesicle isolation were conducted to determine Rab37-mediated IL-6 secretion. STAT3 binding sites at PD-1 promoter in T cells were identified by chromatin immunoprecipitation assay. Multiplex fluorescence immunohistochemistry was performed to detect the protein level of Rab37, IL-6 and PD-1 and localization of the tumor-infiltrating immune cells in allografts from mice or tumor specimens from lung cancer patients.

**Results:** We revealed that Rab37 regulates the secretion of IL-6 in a GTPase-dependent manner in macrophages to trigger M2 polarization. Macrophage-derived IL-6 promotes STAT3-dependent PD-1 mRNA expression in CD8+ T cells. Clinically, tumors with high stromal Rab37 and IL-6 expression coincide with tumor infiltrating M2-macrophages and PD1+CD8+ T cells that predicts poor prognosis in lung cancer patients. In addition, lung cancer patients with an increase in plasma IL-6 level are found to be associated with immunotherapeutic resistance. Importantly, combined blockade of IL-6 and CTLA-4 improves survival of tumor-bearing mice by reducing infiltration of PD1+CD8+ T cells and M2 macrophages in TME.

**Conclusions:** Rab37/IL-6 trafficking pathway links with IL-6/STAT3/PD-1 transcription regulation to foster an immunosuppressive TME and combined IL-6/CTLA-4 blockade therapy exerts potent anti-tumor efficacy.

Key words: Rab37; IL-6; PD-1; transcription; tumor microenvironment

Introduction

Immune cells are known to accumulate in tumor microenvironment (TME) and crucial for regulating tumor progression [1, 2]. Up till now, there are more than 20 immune checkpoints found, and the blockade therapies targeting immune inhibitory receptors such as cytotoxic T lymphocyte associated protein-4 (CTLA-4) and programmed cell-death receptor 1 (PD-1) or its ligand, programmed cell death protein ligand 1 (PD-L1) are now front-line treatments [3-6]. Nevertheless, many patients show primary or acquired resistance to immune checkpoint inhibitors [7, 8]. For example, increased density of
CD11b^F4/80^ or CD163^ tumor associated macrophages (TAMs) has been identified to closely correlate with such resistance [9, 10]. Further, enrichment of exhausted PD-1^CD8^ T cells in melanoma patients correlates with poor response to immunotherapy [11]. The mechanism that induces these potent immunosuppressive cells or exhausted PD-1^CD8^ T cells in TME is not completely clear. In particular, how TME regulates PD-1 upregulation on CD8^ T cells is still a puzzle.

Elevated IL-6 level is linked to chronic inflammatory conditions and observed in many types of cancers [12]. Increased IL-6 in TME will trigger hyperactivation of downstream JAK/STAT3 signaling to drive proliferation, angiogenesis, and metastasis of tumor cells [13-16]. Notably, the increase of IL-6 associated pathways has been found to enhance M2-TAMs and exhausted T cell populations in TME [9, 17]. Although it is known that tumor-infiltrating immune cells are a primary source of IL-6 production in TME, the mechanism of IL-6 secretion is not fully understood.

Rabs are a large group of small GTPases and function as regulators of vesicle trafficking and protein transport. The activity of Rab proteins is controlled by active GTP-bound and inactive GDP-bound forms. Dysregulation of Rab GTPases has been previously reported that Rab37 mediates exocytosis of several secretion factors in non-small cell lung (NSCLC) cells [18, 19]. In addition, Rab37 facilitates soluble IL-1 receptor-like protein secretion in NSCLC cells to antagonize IL-33-mediated M2 macrophage polarization in TME [20]. To date, the role of Rab37 in tumor-infiltrating immune cells remains unknown.

Here, we report that Rab37-mediated exocytosis of IL-6 in NSCLC-associated macrophages promotes their M2 polarization and further PD-1 upregulation in T cells via the Rab37/IL-6/STAT3 transcription axis. Combined blockade of IL-6 and CTLA-4 significantly suppresses lung tumor growth and metastasis in mice. Clinically, NSCLC patients with increased intratumoral Rab37^IL-6^ immune cells where enriched with tumor infiltrated CD163^ M2-TAMs and exhausted PD-1^CD8^ T cells show poor prognosis. Our findings highlight the crucial role of Rab37/IL-6/STAT3 axis in supporting immunosuppressive TME.

Materials and Methods

Generation of Rab37 knockout (KO) mice

The specific mouse Rab37 KO target vector is shown in Figure S1A. The Rab37 gene was deleted before injecting into C57BL/6j (B6) mice using Cre-loxP system to establish the whole body depleted Rab37 KO mice. Embryonic stem cells were selected by neomycin and genotyped by Southern blotting. The selected cells were injected into blastocysts to generate chimeric mice later used for producing Rab37 KO mice. Mouse studies were approved by the Institutional Animal Care and Use Committee of National Cheng Kung University (NCKU) (Permit Numbers: #106255).

Cytokine array

Rab37 positive-related cargo proteins in supernatants of BMDMs derived from wild-type (WT) and Rab37 KO mice were detected with mouse cytokines antibody array-membrane (96 targets) (#ab193659, Abcam, Cambridge, MA, US). Media derived from BMDMs of WT mice and Rab37 KO mice treated with the conditioned media (CM) from mouse Lewis lung carcinoma (LLC) cells were collected at 0 h (MOCK) or 24 h (LCM). The array was performed according to the manufacturer's instructions.

Vesicle isolation and chromatin immunoprecipitation (ChIP) assays

RAW264.7 cells (2.5×10^6) were sonicated and supernatants were obtained by centrifugation (3,000 g for 10 min at 4 °C) and vesicles were enriched from supernatants by high speed centrifugation (30,000 g for 60 min at 4 °C) using a 40-Ti rotor (Beckman, Duarte, CA, US). The vesicles-containing solution (500 µg) was incubated with anti-V5 antibody to isolate Rab37-specific vesicles and the IL-6 cargos in vesicles were analyzed by Western blot (Table S2). For ChIP assay, Jurkat T cells (5×10^6) were cross-linked to prepare nuclear lysates using Magna ChIP™ protein G Kit (Millipore, Cork, Ireland) followed by immunoprecipitation with 5 µg anti-p-STAT3(Y705) antibody (#9145, Cell Signaling, Danvers, MA, US). Q-PCR was carried out using ChIP products. The primer sequences are listed in Table S3.

Allograft tumor growth and metastasis assays in vivo

All animal experiments were performed in compliance with NCKU institutional guidelines for use and care of animals (Permit Numbers: #106255). For α-IL-6 (#MP5-20F3; BioXCell, Lebanon, New Hampshire, US) and α-CTLA-4 (#9H10; BioXCell) treatment, LLC subcutaneous injection and orthotopic injection models were used. For subcutaneous model, 5×10^6 LLC cells were subcutaneously injected into flank of WT or Rab37 KO B6 mice. 1×10^6 LLC cells were suspended in 100 µl PBS for orthotopic model. In both models, 250 µg of IgG, α-IL-6 and/or
α-CTLA-4 were given by intraperitoneal injection in B6 mice harboring LLC allograft. For subcutaneous model, tumor volume was calculated at day 6 and once every five days using the equation \( V = \left(\frac{a^2 \times b}{2}\right) \) during observation. For orthotopic model, mice were sacrificed at day 21 and the primary injected lung and contralateral lungs were removed and resected for RNA/protein extraction, flow cytometry (FLOW) analysis and preserved in paraffin for immunofluorescence immunohistochemistry (IF-IHC) staining. Blood samples were collected for serum biochemistry examinations for toxicity.

**Patient samples and clinical information**

A total of 62 surgically resected lung cancer patients were recruited from NCKU Hospital, after obtaining appropriate institutional review board permission (#B-ER-106-102) and informed consent from the patients. Overall survival was calculated from the day of surgery to the date of death or the last follow-up. Tumor typing and disease staging were performed according to the World Health Organization classification and the TNM classification system, respectively. A total of 16 lung cancer patients receiving clinical α-PD-1 Ab treatment were also recruited (#B-ER-106-102). All patients received regular follow-up at 3-month intervals to evaluate the treatment responses. Partial responders showed no enlargement or newly developed distant metastatic foci on CT scan, while poor non-responders were patients with enlargement or newly developed distant metastatic foci on CT scan. Blood samples were collected at pre-treatment and 3-month on-treatment of α-PD-1 therapy for ELISA analysis. The detailed clinicopathological characteristics of patients are listed in Table S4.

**Statistical analysis**

Cell studies were conducted in three independent experiments unless indicated otherwise. The number of mouse per group for animal studies was described for each experiment. Two-tailed Student’s t test was used. Data represented mean ± SD. Pearson χ² test was used to compare the correlation of Rab37, IL-6, CD45, CD163, CD8 or PD-1 protein expression in lung cancer patients. Overall survival curves were calculated according to the Kaplan-Meier method, and comparison was performed using the log-rank test. Cox regression comparison was performed to analyze the relative risk for patient poor outcome. The level of statistical significance was taken as p value, *: p < 0.05; **: p < 0.01; ***: p < 0.001.

Detailed methods are enclosed in the online supplemental materials and methods section.

**Results**

**Rab37-/− KO mice provide an anti-tumor microenvironment to inhibit tumor growth**

To understand how Rab37 expression in the stromal cells impacts lung cancer progression, we generated whole-body Rab37 KO mice in C57BL/6 background (Figure S1A). Rab37 deficiency was confirmed at mRNA and protein levels (Figure 1A, S1B). We then observed for tumor growth of the subcutaneous syngeneic mouse LLC allograft model in WT and Rab37 KO mice. The results showed that LLC tumor growth in Rab37 KO mice was inhibited compared to that in WT mice (Figure 1A). We further examined physiological relevance of Rab37 KO in tumor metastasis using tail-vein injection model. The size and number of metastatic cancer nodules in lungs were lower in Rab37 KO mice than in WT mice (Figure S1C-E). These results suggested that depletion of stromal Rab37 created an anti-tumor microenvironment in the primary site and in metastatic niches.

Next, we collected endpoint subcutaneous LLC allografts to analyze tumor-infiltrating T cells and macrophages by FLOW analysis (Figure 1B). Tumor-infiltrating CD8+ T cells derived from Rab37 KO mice showed reduced PD-1 expression compared to those from WT mice, indicating Rab37 involvement in PD-1 expression on CD8+ T cells. FLOW analyses further revealed that the allografts derived from Rab37 KO had decreased number of Tregs and CD206+ M2 macrophages compared to WT mice (Figure 1B). The IF-IHC results confirmed that Rab37 deficiency increased CD8+ T cells and M1 macrophages, but decreased Tregs and M2 macrophages in the TME of LLC primary allografts (Figure 1C) and metastatic lung tumor sections (Figure S1F). These findings uncovered a pro-tumor role of stromal-residing Rab37 in fostering an immunosuppressive TME.

**Rab37 in stromal immune cells links immuno-suppression to tumor-promoting phenotypes**

Next, we investigated the contribution of Rab37 in endogenous immune response to LLC tumor. We first isolated splenocytes from Rab37 WT and KO mice and stimulated them with anti-CD3/CD28 antibodies. FLOW analysis results showed that the percentage of CD8+ T cells from Rab37 KO mice was increased as compared to Rab37 WT mice upon anti-CD3/anti-CD28 stimulation (Figure 1D). Moreover, CD8+ T cells from Rab37 KO mice had significantly reduced surface PD-1 (Figure 1E). Importantly, exhausted CD8+ T cell subpopulation (PD-1+Tim-3+CD8+) was significantly lower in T cells from Rab37 KO mice compared with WT mice (Figure 1F). In addition, the ELISA results
showed an increase of IFN-γ secretion upon anti-CD3/anti-CD28 stimulation (Left, Figure 1G) and the lymphocyte-mediated cytotoxicity against cancer cell assay demonstrated an enhanced cancer cell killing effect of CD8+ T cells from Rab37 KO mice (Right, Figure 1G). The isolated splenic CD8+ T cells were then treated with LLC conditioned medium (LLC-CM). LLC-CM treatment increased the PD-1 expression on WT CD8+ T cells compared to those from Rab37 KO mice (Left, Figure 1H). Moreover, the amount of Treg was also decreased in Rab37 KO splenocytes compared to WT cells upon LLC-CM treatment, although no significant differences were observed in LCC-CM and MOCK groups of WT Tregs due to the lack of T cell receptor signaling upon LLC-CM treatment (Right, Figure 1H). Together, these results revealed that splenic T cells of Rab37 KO mice had enhanced proliferation, cytokine production and cytotoxicity against cancer cells.

We further examined the role of Rab37 in macrophages by isolating BMDMs from WT and Rab37 KO mice. BMDMs were then induced towards

Figure 1. Rab37 in stromal immune cells links immunosuppression to tumor-promoting phenotypes. (A) Tumor growth of the subcutaneous syngeneic mouse LLC allograft (1 x 10^6 cells inoculated) in Rab37 WT and KO C57BL/6 mice. Immunoblots of Rab37 expression are shown. (B, C) Tumor-infiltrating T cells and macrophages of endpoint tumor on day 22 were analyzed by FLOW (B) or IF-IHC (C). Scale bars: 20 µm. (D-F) Total CD8+ cells (D), PD-1+CD8+ cells (E), and PD-1+Tim-3+CD8+ cells (F) of isolated splenocytes from tumor-free Rab37 WT or KO mice upon stimulation by anti-CD3 and anti-CD28 antibodies for 48 h. (G) Left: IFN-γ secretion on splenic CD8+ T cells from tumor-free Rab37 WT or KO mice upon anti-CD3/anti-CD28 stimulation. Right: WT and Rab37 KO mouse effector splenocytes (E) were co-cultured with Luciferase-transduced mouse LLC cancer target cells (T) at various E:T ratios for 48 h to determine the cytotoxicity against cancer cells. (H) Analysis of PD-1 expression on CD8+ T (left) and Treg population of CD4+ T (right) splenocytes upon ex vivo treatment with LLC-CM (conditioned media). (I) mRNA level of Arg1, Fizz1, Ym1 (M2) and IL-12 (M1) by RT-qPCR after M2 stimulator IL-13 treatment in isolated Rab37 WT and KO BMDMs. (J) Analyses of percentage of F4/80+CD206+ by FLOW after LLC-CM treated Rab37 WT and KO BMDMs. Data represent mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001, Student’s t-test.
M2 polarization by stimulating with IL-13. RT-qPCR results showed that Rab37 KO BMDMs displayed reduced expression of M2 associated genes (Arg1, Fizz1 and Ym1) as compared to WT cells. Conversely, Rab37 KO BMDMs showed enhanced expression of M1 marker IL-12 gene even upon IL-13 stimulation (Figure 1I). Notably, FLOW data indicated that LLC-CM treatment induced M2 surface marker CD206 on WT BMDMs in response to LLC-CM treatment (Figure 1J). Together, these findings reveal previously unrecognized functions of Rab37 in promoting pro-tumorigenic M2 type macrophage polarization and limiting cytotoxic T cell activity.

**Cytokine/chemokine array and ELISA identify cargo candidates of Rab37 in macrophages**

Several exocytic Rab small GTPases have been reported to target the release of immune modulating proteins to shape the TME [21]. Thus far, TNFα is the putative cytokine cargo identified for Rab37 in macrophage and T cells [22, 23]. To identify the potential cargos of Rab37 in macrophages, one of the major immune cells to infiltrate TME, LLC-CM educated WT and Rab37 KO BMDMs were collected and subjected to cytokine/chemokine array analyses (Figure 2A). Our data demonstrated that the secretion levels of several cytokines and chemokines including IL-6 were decreased in Rab37 KO BMDMs compared with WT BMDMs at basal level or upon LLC-CM stimulation. The increase of IL-6 associated pathways has been found to enhance M2-TAMs and inactivated T cell populations in TME [9, 17]. Therefore, we selected IL-6 as target candidate of Rab37-mediated exocytosis and explored the impact of IL-6 modulated pathways in fostering an immunosuppressive TME.

ELISA assay confirmed that the secretion levels of IL-6 were decreased in LLC-CM educated Rab37 KO BMDMs compared to WT BMDMs (Figure 2B). Since Rab37 is a small GTPase regulated by GTP or GDP, we expressed empty vector control (EV), Rab37 wild-type (Rab37WT), constitutively active Rab37-GTP mutant (Rab37Q89L) and dominant negative Rab37-GDP mutant (Rab37T43N) in RAW264.7 murine macrophage cell line. ELISA data showed that IL-6 level was elevated in CM from Rab37WT and Rab37Q89L, but reduced in Rab37T43N RAW264.7 cells (Figure 2C). These data suggest that Rab37 mediates IL-6 secretion in macrophages in a GTPase-dependent manner.

**IL-6 is a trafficking cargo of Rab37 in macrophages**

To investigate whether Rab37 directly regulates exocytosis of IL-6 in macrophages, we conducted confocal analysis to demonstrate that Rab37 co-localized with IL-6 in WT BMDMs (Left, Figure 2D), while the co-localization signals disappeared in Rab37 KO BMDMs (Right, Figure 2D). In addition, Rab37 co-localized with IL-6 to form yellow fluorescent in Rab37WT and Rab37Q89L cells, whereas Rab37 and IL-6 were distributed to distinct regions in the Rab37T43N cells (Figure 2E).

Next, to demonstrate the presence of IL-6 in the Rab37-containing vesicles, we overexpressed V5-tagged EV and Rab37WT in RAW264.7 cells and performed vesicles isolation to immunoprecipitate Rab37-specific vesicles with anti-V5 beads. The vesicle IP-western blots showed that IL-6 was enriched in Rab37-specific vesicles isolated from Rab37WT RAW264.7 cells (Figure 2F). To further confirm the ultrastructure of Rab37-mediated vesicle recruitment of IL-6, we performed immuno-transmission electron microscopy on cancer CM treated THP-1 human monocyte cells. Strikingly, IL-6 was localized in Rab37-associated vesicles in THP-1 cells (Figure 2G, I), which was further enhanced by cancer-CM (Figure 2H-I). Colocalization of IL-6 with Rab37-containing vesicles was increased in close proximity of plasma membrane (PM) in the cancer-CM treated THP-1 monocytes (Regions 3 and 4, Figure 2H). Moreover, IL-6 colocalized with Rab37 in the WT BMDMs (Figure S2A), but not in Rab37 KO BMDMs (Figure S2B). Collectively, these results demonstrate that IL-6 localizes in Rab37-containing vesicles in macrophages.

For real-time visualization of Rab37-regulated IL-6 trafficking, we performed time-lapse confocal microscopic analysis of GFP-tagged EV, Rab37WT, Rab37Q89L, or Rab37T43N RAW264.7 macrophage cells co-transfected with RFP-tagged IL-6 expression vector (Figure 2J-M, Movie S1-S4). In Rab37WT RAW264.7 cells, IL-6 (red) was progressively taken up into Rab37 (green) punctate vesicular structures to form colocalization vesicles (yellow) and then rapidly released for another run of Rab37-mediated trafficking (Figure 2K). In Rab37Q89L RAW264.7 cells, more colocalized puncta and faster trafficking were observed as compared to Rab37WT cells (Figure 2L). In Rab37T43N RAW264.7 cells, Rab37 and IL-6 punctate structures appeared in distinct compartment (Figure 2M). We also employed TIRF microscopy analysis for selective visualization of fluorescently labeled vesicles located in close proximity to the PM (Figure S2C-E, Movie S5-S6). To the best of our knowledge, this is the first report on the dynamics of Rab37-mediated trafficking and docking of IL-6-containing vesicles.
Figure 2. Rab37 mediates IL-6 secretion in macrophages in a GTPase-dependent manner. (A) Heatmap depicting the secretin level of cytokines/proteins in CM derived from untreated or LLC-CM treated BMDMs from Rab37 WT and KO mice. IL-6 is indicated by an arrow. (B, C) ELISA was performed to validate the level of IL-6 in CM from Rab37 WT and KO BMDMs (b) or in CM from EV, Rab37WT, Rab37T43N, or Rab37Q89L RAW264.7 cells (C). (D, E) Confocal microscopy images of Rab37 (green), IL-6 (red) and nucleus staining (blue) in Rab37 WT and KO BMDMs (D) or in EV, Rab37WT, Rab37Q89L, or Rab37T43N RAW264.7 cells (E). Z-stack images are shown. Scale bars: 10 µm. (F) Vesicles of EV or Rab37WT RAW264.7 cells expressing V5-tagged Rab37, were collected by centrifugations and immunoprecipitated (IP) with anti-V5 and vesicle lysates were blotted for V5-Rab37 and endogenous IL-6. (G-I) Ultrastructural localization of Rab37 (10 nm of gold, red arrow) and IL-6 (20 nm of gold, yellow triangle) illustrated by immuno-EM images of control THP-1 (G) or A549-CM treated THP-1 macrophages (H). PM: plasma membrane. Scale bars: 500 nm. Enlarged images shown in insets of the representative regions. (I) Rab37/IL-6 colocalized vesicles were significantly increased in the A549-CM treated THP-1 compared to those in the control THP-1 cells. An average of 15-25 vesicles per cell and a total of 10 cells were collected. Percentages are expressed in relation to the total number of Rab37 specific vesicles. (J-M) Selected frames from time-lapse confocal movies of GFP-tagged EV, Rab37WT, Rab37Q89L, or Rab37T43N RAW264.7 cells co-transfected with RFP-tagged IL-6 cells. Enlarged images of the boxed areas with time intervals in seconds are shown (bottom). Arrow indicates trafficking vesicle. Scale bars: 10 µm. Data represent mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001, Student’s t-test.

Rab37-mediated IL-6 secretion promotes M2 macrophage polarization via STAT3 activation

Previous studies suggested that IL-6 promotes M2 polarization by activating STAT3 [24]. Yet, STAT1 activation drives M1 macrophage polarization [25]. This prompted us to examine the STAT3 and STAT1 activation in EV, Rab37WT, Rab37Q89L and Rab37T43N...
expressing RAW264.7 cells. Western blot data showed that p-STAT3 level was elevated in Rab37Q89L RAW264.7 cells whereas p-STAT1 level was down-regulated in Rab37WT and Rab37Q89L RAW264.7 cells (Figure 3A). Additionally, IF results demonstrated that nuclear localization of p-STAT3 was enhanced in WT BMDMs comparing to Rab37 KO BMDMs (Upper and Right, Figure 3B), while decreased nuclear localization of p-STAT1 was observed in WT BMDMs (Upper and Right, Figure 3C). We further performed reconstitution analyses in Rab37WT cell treated with neutralizing IL-6 antibody (α-IL-6). The immunoblotting results showed that treatment of α-IL-6 attenuated Rab37WT-induced p-STAT3 signals (Figure 3D). These results support the notion that Rab37 mediates IL-6 secretion in macrophages to up-regulate STAT3 and down-regulate STAT1 transcription program.

To explore the role Rab37 in promoting M2-polarization, we treated BMDMs isolated from WT or Rab37 KO mice with LLC-CM. FLOW analysis demonstrated that LLC-CM treatment efficiently induced M2 polarization in Rab37 WT BMDMs (F4/80+CD206+), which was reduced by α-IL-6 treatment (Figure 3E). Notably, α-IL-6 greatly reduced the mRNA level of M2 marker genes (Fizz1 and Ym1) and induced the M1 genes (IL-12 and NOS2) in BMDMs (Figure 3F-G). The LLC-CM induced M2 polarization in Rab37 WT BMDMs was reduced by α-IL-6 treatment (Figure 3F-G). Together, these results suggest that Rab37 mediates IL-6 secretion to skew M2 macrophage polarization by enhancing STAT3 but reducing STAT1 signal.
Macrophage-derived IL-6 promotes PD-1 expression in T cells via the Rab37/IL-6/STAT3 trafficking and transcription axes

Notably, blockade of IL-6 by α-IL-6 also attenuated PD-1 upregulation on WT CD8+ T cells upon LLC-CM treatment (Figure 4A). Therefore, we hypothesized that Rab37-mediated IL-6 secretion by macrophages promotes PD-1 expression on CD8+ T cells. Importantly, depletion of macrophages by clodronate liposomes injection into mice largely constrained IL-6 level in TME of LLC allografts (Figure 4B, S3A-B), supporting that macrophages are responsible for IL-6 production in TME in vivo. Strikingly, macrophage depletion not only elicited an immune activated TME to attenuate tumor growth (Figure S3C-F) but also reduced the tumor-infiltrating PD-1+CD8+ T cells (Figure 4C), suggesting that PD-1 expression on CD8+ T cells may be stimulated by the IL-6 produced by macrophages.

We undertook a co-culture approach to verify that Rab37-mediated IL-6 secretion in TME regulates
PD-1 expression on T cells (Figure 4D). The cell types in the co-culture system included human THP-1 macrophages, human Jurkat T cells and A549 lung cancer cells. The A549 lung cancer cell line was chosen because its intrinsic Rab37 was expressed at a higher level than other lung cancer cells (Figure S4). The macrophage-derived IL-6 secretion and PD-1 expression in T cells, verifying the role of Rab37-mediated IL-6 secretion in macrophage cells plays an important role in cross-talk between cancer cells, macrophages and T cells (Bar 7, Figure 4E). Blockade of IL-6 by α-IL-6 attenuated the IL-6 levels in mixed CM in a dose-dependent manner (Bar 8-9, Figure 4E). These results reinforce the conclusion that macrophages largely contributed to the production of IL-6 in mixed culture of cancer cells, macrophages and T cells.

Next, we determined whether macrophage-derived IL-6 promoted PD-1 expression in T cells via the Rab37/IL-6/STAT3 transcription axis. To this end, we employed RT-qPCR analyses of PD-1 mRNA expression in Jurkat T cells cultured under the co-culture conditions (Figure 4D). A significant increase of PD-1 mRNA in Jurkat T cells cultured with mixed CM of cancer cells, macrophages and T cells was observed (Bar 4, Figure 4F), while culture with CM from Rab37 silenced THP-1 macrophages (Bar 5, Figure 4F) or blockade of IL-6 by α-IL-6 (Bars 6-7, Figure 4F) markedly attenuated PD-1 expression in T cells, verifying the role of Rab37-mediated IL-6 derived from macrophages in mediating PD-1 expression in T cells.

To unravel the regulatory mechanisms of IL-6 secretion and PD-1 expression in T cells, we examined the binding of STAT3 transcription factor to the PD-1 promoter in T cells. We first identified three STAT3 putative binding sites at PD-1 promoter (Figure 4G). Next, chromatin-immunoprecipitation (ChIP)-qPCR results showed significant increase in p-STAT3 binding to the PD-1 promoter and such binding was largely attenuated by α-IL-6 treatment at the three regions examined (Figure 4H). These results provide evidence that macrophage-derived IL-6, in the paracrine manner, promotes PD-1 membrane presentation on T cells via the Rab37/IL-6/STAT3 trafficking and transcription axes.

CTLA-4 and IL-6 blockade combination therapy reduces tumor progression in a subcutaneous and an orthotopic model of lung cancer

Our results so far provide a new mechanism that Rab37 mediates the exocytosis of IL-6 to increase PD-1 expression on CD8+ T cells, suggesting that Rab37/IL-6/STAT3/PD-1 functions in the same axis in fostering an immunosuppressive lung TME. Indeed, the anti-tumor effects of anti-PD-1 antibody (α-PD-1) therapy were abrogated in Rab37 KO mice (Figure S5A). In addition, the anti-tumor effects of JAK2/3 inhibitor AG490 was observed in WT mice but not in Rab37 KO mice (Figure S5B), consistent with the hypothesis of Rab37/IL-6/STAT3/PD-1 functioning in the same axis.

In addition to PD-1, another inhibitory receptor CTLA-4 has been reported to inhibit T cell proliferation and activation [3, 4]. The Rab37/IL-6/STAT3/PD-1 axis in immune cell models prompted us to determine whether concurrent blockade of IL-6 and CTLA-4 in vivo would provide a rational treatment to circumvent current PD-1-targeted immune-modulatory therapy for lung cancer. First, we tested the therapeutically efficacious co-administration of α-IL-6 and anti-CTLA-4 antibody (α-CTLA-4) on LLC tumor growth in subcutaneous model (Figure 5A). We found that combination of α-IL-6 and α-CTLA-4 further inhibited tumor growth compared to IgG control groups and other single treatments (Figure 5B). Importantly, α-IL-6 treatment did not show any significant effect on Rab37 KO mice, indicating that the beneficial effects of α-IL-6 and/or α-CTLA-4 treatment are dependent on the expression of Rab37 (Figure 5C). The FLOW results showed that the percentage of CTLA-4+PD-1+ on CD4+ cells (Upper, Figure 5D) and FoxoP3+CD25+ on CD4+ immunosuppressive Tregs (Lower, Figure 5D) were lower in tumor allografts from combined treatment compared to other single treatments. The reduction of CTLA-4+PD-1+CD8+ cells and Tregs could also be seen in the PBMC collected on day 10 during treatment (Figure S5C). Overall, α-IL-6 and α-CTLA-4 combination treatment reprogrammed to T helper 1 inflammation as determined by FLOW (Figure S5D).

Next, we tested the efficacy of co-administration of α-IL-6 and α-CTLA-4 on lung orthotopic model in which LLC cells were inoculated percutaneously into the left lateral thorax, and the tumor nodules in the right lungs of injected mice were considered as metastatic lesions (Figure 5E). Strikingly, combined treatment not only significantly decreased the primary tumor growth (Figure 5F-G) but also reduced lung to lung tumor metastases compared to the...
control (Figure 5F, H). Importantly, combined treatment prolonged mouse survival (Figure 5I). The ELISA results in animal model showed a positive correlation of plasma IL-6 level with tumor size (Figure 5J). Notably, treatment with antibody blocking IL-6, CTLA-4 or both did not result in any overt signs of toxicity measured by serum biochemistry analysis in all animals tested (Figure S5E). Therefore, α-IL-6 and α-CTLA-4 combination treatment led to effective and long-lasting anti-tumor activity.

**Combined blockade of IL-6 and CTLA-4 increases infiltration of CD8+ T cells and M1 macrophages into LLC tumors in vivo**

Multi-color IF-IHC was performed on the LLC allograft tissues. There were less infiltrating CD8+ cells in tumor derived from IgG group and the CD8+ cells were mainly localized in tumor edge (Figure 5K). Combination treatment promoted more CD8+ cells infiltrating into tumor core (Figure 5L). Strikingly, more M2 macrophages (CD206) and less M1 (CD86) infiltrated into the tumor core in control IgG group.

Figure 5. Combined blockade of CTLA-4 and IL-6 provides synergistic anti-tumor efficacy with reactive immune responses in vivo. (A) LLC (5 x 10^5) subcutaneous model in Rab37 WT and KO mice with α-IL-6 and/or α-CTLA-4 treatments. (B, C) Tumor volume of LLC allograft in Rab37 WT (b) and KO (c) mice upon treatment. (D) Tumor-infiltrating PD-1+ and CTLA-4+ on CD4+ cells (upper) and Treg cells (lower). (E) Lung orthotopic model with LLC (1 x 10^4 cells) injected into the left lung. The administration protocol of α-CTLA-4 and/or α-IL-6 was the same as that in subcutaneous model. (F) Representative H&E-stained sections of primary tumor (P) in the left lung and metastatic tumors (m) in the right lateral lungs in mouse of four treatment groups. (G, H) Overall area of tumor nodules of primary tumors (G) and metastatic tumors (H) in four treatment groups. (I) Survival curves were measured in LLC orthotopic mouse model. (J) The concentration of IL-6 in the plasma from treated mice measured on the indicated days. (K, L) Distribution of CD8+ T cells (green) by IF-IHC in orthotopic lung model in IgG control group (K) and combined treatment group (L). (M, N) Distribution of M1 (green) and M2 (red) macrophages in control group (M) and combined treatment group (N). Blue fluorescence represents the nucleus staining. Scale bar: 100 µm. Data represent mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; ns non-significant, Student's t-test.
(Figure 5M), whereas the infiltrating population of M1 macrophages increased in tumor core and M2 macrophages located toward the tumor boundaries after combined treatment (Figure 5N). These results demonstrated that combination of α-IL-6 and α-CTLA-4 therapies shaped TME to a T helper 1 immunity to suppress tumor growth and metastasis.

**Rab37 and IL-6 are concordantly expressed in infiltrating immune cells of tumor from NSCLC patients with poor prognosis**

The relationship between stromal Rab37 and IL-6 expression has never been examined in TME of human cancer patients. Therefore, we performed multiplex IF-IHC with Rab37, IL-6 and CD45 staining for tumor-infiltrating immune cells on tumor specimens from 62 NSCLC patients. IF-IHC demonstrated that co-expression of intracellular Rab37 and IL-6 are concordantly expressed in human cancer patients. Therefore, we performed multiplex IF-IHC with Rab37, IL-6 and CD45 staining for tumor-infiltrating immune cells on tumor specimens from 62 NSCLC patients. IF-IHC demonstrated that co-expression of intracellular Rab37+ and IL-6+ (Figure 6C) was observed especially in late stage patients (Figure S6 A-B). Patients with high proportion of CD45+Rab37+IL-6+ cells per region of interest (ROI) were significantly associated with advanced tumor stage (stages III and IV; P < 0.01) (Figure 6A).

We further investigated whether patients with intratumoral CD45+Rab37+IL-6+ expression profile correlated with cancer progression and poor prognosis. A total of 33.9% (21/62) patients showed CD45+Rab37+IL-6+ high expression (Table 1). Of note, patients with high intratumoral CD45+Rab37+IL-6+ expression were significantly associated with advanced tumor stage (P < 0.001), lymph node metastasis (P = 0.025) and distal metastasis (P = 0.003) (Table 1). Importantly, we performed Kaplan-Meier analysis on 42 NSCLC patients whose overall survival data were available. NSCLC patients with high proportion of intratumoral CD45+Rab37+IL-6+ cells correlated significantly with unfavorable outcome than those with low proportional ones (Figure 6B).

**Rab37+IL-6+ tumors are associated with intra-tumoral M2-TAMs (CD163+) and exhausted T cells (PD-1+CD8+) in lung cancer patients**

To verify if CD45+Rab37+IL-6+ tumors elicited an immunosuppressive TME, we next examined whether the intratumoral M2-TAMs (CD163+) and exhausted T cells (PD-1+CD8+) were accompanied by high infiltration of CD163+ (R square = 0.438, P < 0.01, n = 20) (Figure 6E) and/or PD-1+CD8+ cells (R square = 0.326, P < 0.01, n = 20) (Figure 6F). These clinical results demonstrated, for the first time, that stromal Rab37 was characterized by a distinct pro-tumor immune microenvironment with a high level of intratumoral IL-6 adjacent to M2-macrophages and PD-1+CD8+ exhausted T cells to elicit an immunosuppressive TME, leading to poor prognosis of NSCLC patients.

**Table 1. Expression profile of intratumoral CD45+Rab37+IL6+ levels in relation to clinicopathological parameters in 62 NSCLC patients**

| Clinicopathologic parameters | CD45+Rab37+IL6+ cells (%) | p value |
|-----------------------------|---------------------------|---------|
|                            | Total | Low (%) (66.1%) | High (%) (33.9%) |         |
| Stage                      |        |                 |                  |         |
| Stage I-II                 | 32     | 28 (87.5)       | 4 (12.5)         |         |
| Stage III-IV               | 30     | 13 (43.3)       | 17 (56.7)        | < 0.001 |
| N stagea                   |        |                 |                  |         |
| N0                         | 27     | 22 (81.5)       | 5 (18.5)         |         |
| N ≥ 1                      | 35     | 19 (54.3)       | 16 (45.7)        | 0.025   |
| M stageb                   |        |                 |                  |         |
| M0                         | 53     | 39 (73.6)       | 14 (26.4)        |         |
| M ≥ 1                      | 9      | 2 (22.2)        | 7 (77.8)         | 0.003   |

* Categorical data were presented as the mean.
* The data were analyzed by Pearson χ² test.
* N Stage: lymph node metastasis; M Stage: distal organ metastasis.

**Change in the plasma IL-6 level reflects the therapeutic efficacy of α-PD-1 treatment in lung cancer patients**

Our ELISA results in animal model showed a positive correlation of plasma IL-6 level with tumor size (Figure 5J). In addition, our clinical data showed that IL-6+ signals in TME were stronger in tumor derived from advanced stage patients than those from early ones (Figure 6C). Therefore, we examined whether plasma level of IL-6 correlated with therapeutic efficacy of α-PD-1 treatment in NSCLC patients. ELISA assay was performed on plasma samples derived from 16 NSCLC patients receiving α-PD-1 immunotherapy whose sequential blood samples were available. Patients were divided into two groups: poor treatment response (SD, stable disease) and partial response (PR). Strikingly, SD
patients were associated with greater increase in plasma IL-6 levels during α-PD-1 treatment (on-/pretreatment; median value, 1.38-fold) compared with PR patients (on-/pretreatment; median value, 0.72-fold) (Figure 6G-H). These results implicated that an increase in plasma IL-6 level during PD-1 blockade correlates with poor therapeutic responsiveness of NSCLC patients.

Discussion

Here, we reveal novel findings that Rab37, a regulator of vesicle transport and protein trafficking, acts as a tumor promoter in stromal cells. Rab37 mediates IL-6 secretion and STAT3 transcription activation leading to M2 macrophage polarization and upregulation of PD-1 on CD8+ T cells, ultimately
establishing an immunosuppressive TME (Figure 7). We and others have previously described the mechanism by which Rab37 gene expression is downregulated by promoter hypermethylation in cancer cells [26, 27]. Until now, promoter methylation of Rab37 has not been observed in immune cells where Rab37 is expressed in a pleiotropic manner. For example, Rab37 is expressed in secretory granules of mast cells to regulate mast cell degranulation [28]. In cytotoxic CD8+ T cells, Rab37 has been found in recycling endosomes [29]. In CD4+ T helper cells, Rab37 is suggested to be associated with secretion of IL-2, IL-4 and TNF-α [22]. Interestingly, gene expression of Rab37 was found to be upregulated in skin wounds and LPS-stimulated macrophages indicating that Rab37 may participate in both tissue inflammation and repair [23]. Together, these published results and our data suggest that Rab37 is a critical protein in modulating immune cells in physiological and pathological conditions.

IL-6 is a pleotropic pro-inflammatory cytokine, thereby contributing to the dysfunction of innate and adaptive immune responses against tumors [30]. However, the secretion mode of IL-6 is not fully understood. In this study, we identified IL-6 as a secretory cargo protein of Rab37 in TAMs. A study has shown that TAM-derived IL-6 promotes mouse lung tumor growth through activation of STAT3 [31]. Notably, the downstream signal pathways of immunosuppressive cytokine transforming growth factor-β (TGF-β) can also promote T cell dysfunction in the TME. For example, Stephen and associates showed that tumor-derived TGF-β activates Smad3 to increase PD-1 expression by inhibiting the chromatin organizer Satb1 in tumor-reactive T cells [32]. Furthermore, TGF-β combined with IL-6 induces the expression of transcription factor Maf, a potential driver of dysregulation of CD8+ T cells in TME [33]. On the other hand, several previous studies showed that TLR4-induced NF-κB signaling pathway was able to facilitate IL-6 expression via stabilization of IL-6 mRNA in macrophages [34, 35]. Additionally, LLC tumor-induced increase of circulating TNF-α and IL-6 was abolished in TLR4 KO mice [36]. These findings suggest that TLR4-mediated signaling may participate in IL-6 production, perhaps also for Rab37 activation, in lung M2-TAMs.

We discovered that macrophage-derived IL-6 served as a paracrine signal to up-regulate PD-1 mRNA expression in T cells through STAT3 transcriptional control. Indeed, immunoreactivity of p-STAT3 in TME correlates with expression of PD-1+ stromal cell [37]. Moreover, IL-6/STAT3 signal may cooperate with other factors in TME to induce PD-1 mRNA expression in T cells [38]. Previous studies reported that Pdcd1 gene in T cells can be positively regulated by STAT3, NFATc1, FoxO1, and NF-κB, or negatively controlled by Blimp-1 and T-bet [39-42]. Using ChIP assay, we identified three STAT3 binding sites at Pdcd1 promoter at -3568 ~ -3419, -3506 ~ -3311 and -1709 ~ -1506, which are located close to the two previously reported DNase I hypersensitive sites at -3.7 kb and -1.1 kb [38]. It is worth noting that these sites can also be bound by NFATc1 and NFκB [37]. Moreover, chromatin landscape of Pdcd1 gene locus was dynamically changed during T cell stimulation and cytokine exposure [38, 41, 43]. Nevertheless, our model of the converged Rab37/IL-6/STAT3 trafficking and transcription axis adds a new layer of PD-1 transcriptional regulatory mechanisms.
Development of effective therapeutics to ameliorate the immunosuppressive TME in cancer patients is eagerly anticipated [44]. Our results suggest that Rab37/IL-6/PD-1 functions in the same axis and thus provide a rationale design using combined treatment of α-IL-6 and α-CTLA-4 to promote anti-tumor efficiency. Several studies have shown that inhibition of IL-6 enhances the therapeutic efficacy of α-PD-L1 therapy in melanoma, colorectal cancer, pancreatic cancer and hepatocellular carcinoma [45-48]. Intriguingly, the beneficial effect of combination therapy with α-IL-6 and α-PD-1 has not been reported, supporting our notion that IL-6 and PD-1 work in the same pathway. In addition, we found that plasma IL-6 level reflects the therapeutic efficacy of α-PD-1 treatment in NSCLC patients. Consistently, an increase in circulating IL-6 in anti-PD-1 therapy has been shown to correlate with the development of pathologic immune-related adverse events [49, 50]. Therefore, our study not only provides an efficient way for patients with resistance to anti-PD1/PD-L1 therapy to recover from immunosuppressive status but also a potential biomarker using plasma IL-6 level for patients selection to receive dual IL-6/CTLA-4 blockade therapy.

Our clinical data corroborated with in vitro and in vivo experiments that infiltration of intratumoral Rab37+IL-6+ immune cells enriched with CD163+ M2 macrophages is a feature of high density of PD-1+ CD8+ exhausted T cells. IL-6 is reported to induce the expression of M2-like macrophages and granulocytic myeloid-derived suppressor cells, and protumor T-regulatory/Th17 cell responses, whereas reducing anti-tumor ability of Th1 and CD8+ T cells [51, 52, 53]. Note that increased level of IL-6 in patients treated with immune checkpoint blockade is associated with poor responses and survival [54-56]. The intratumoral spatial pattern of Rab37+IL-6+CD163+CD8+PD1+ defined by IF-IHC or high IL-6 of plasma ELISA as biomarkers would identify patients in dire need of intensive surveillance and further combination therapy with α-IL-6 and α-CTLA-4 antibodies would improve their clinical outcome.

In conclusion, we found that Rab37-mediated exocytosis of IL-6 from macrophages promotes PD-1 upregulation in T cells via the Rab37/IL-6/STAT3 transcription axis to support lung cancer progression. Combined blockade of IL-6 and CTLA-4 suppressed lung tumor growth in mice by increasing tumor-infiltrating CD8+ T cells and M1 macrophages. Clinically, NSCLC patients with high intratumoral CD45+Rab37+IL-6+ or IL-6+CD163+CD8+PD-1+ immunoreactivity or an increase in plasma IL-6 level are found to be significantly associated with poor prognosis or therapeutic resistance. This study uncovers a novel function of Rab37 in suppressing tumor immunity and adds a new insight into the complexity of PD-1 regulation. Our findings provide a rationale and feasible combined therapeutic approach targeting IL-6 and CTLA-4 in lung cancer patients.

Supplementary Material
Supplementary figures and tables.
http://www.thno.org/v11p7029s1.pdf
Supplementary movie S1.
http://www.thno.org/v11p7029s2.avi
Supplementary movie S2.
http://www.thno.org/v11p7029s3.avi
Supplementary movie S3.
http://www.thno.org/v11p7029s4.avi
Supplementary movie S4.
http://www.thno.org/v11p7029s5.avi
Supplementary movie S5.
http://www.thno.org/v11p7029s6.avi
Supplementary movie S6.
http://www.thno.org/v11p7029s7.avi

Acknowledgements
We thank the technical services provided by the “Transgenic Mouse Model Core Facility” and “The i-MANI center” of the National Core Facility for Biopharmaceuticals, Ministry of Science and Technology, Taiwan as well as the technical service from the “Animal Resources Laboratory of National Taiwan University Center of Genomic and Precision Medicine” and from the “Instrument Development Center of the National Cheng Kung University”. We acknowledge Dr. Ruey-Hwa Chen, Institute of Biological Chemistry at Academia Sinica and Dr. Shu-Han Yu, Institute of Biotechnology at National Taiwan University for discussion and comments on the manuscript.

This work was supported by Taiwan Ministry of Science and Technology grants MOST 106-2321-B-006-023 and MOST 107-2321-B-006-020.

Contributors
Y.-C.W. conceived the project; I.-Y.K., C.-P.C. and Y.-C.W. designed the experiments; I.-Y.K., Y.-E.Y., P.S.Y., Y.-J.T., H.-T.T. and W.-T.K. performed and analyzed experiments; H.-C.C. helped I.-Y.K., Y.-E.Y. to perform the animal experiments; W.-C.S. provided clinical samples; Y.-C.W. and C.-P.C. wrote the manuscript with edits from all authors; Y.-C.W. obtained funding.
Competing Interests
The authors have declared that no competing interest exists.

References
1. Binnewies M, Roberts BW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24: 541-50.
2. Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor immune microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020; 11: 940.
3. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39: 98-106.
4. Chae KY, Aria A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape of immunotherapy. Semin Immunol. 2014; 26: 38-47.
5. Ikri T, Ohnishi K, Fujitani Y, Horlach H, Saito Y, Pan C, et al. The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer. 2017; 106: 22-32.
6. Stephen TL, Payne KK, Chaurio RA, Allegrezza MJ, Zhu H, Perez-Sanz, et al. T cellBA1 expression governs epiregic repression of PD-1 in tumor-reactive T cells. Immunity. 2017; 46: 51-64.
7. Mirandolino H, Henin C, Madon J, Imbratta C, Bourdelle P, Buneuf M, et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 2015; 34: 2042-58.
8. Masuda K, Ripley B, Ninuma R, Mino T, Takeuchi O, Shiigi G, et al. Aripiril controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in sera. Proc Natl Acad Sci U S A. 2013; 110: 9409-14.
9. Nyati KK, Masuda K, Zaman MM, Dubey PK, Millrine D, Chalise JP, et al. TLR4-induced NF-kappaB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Aripiril. Nucleic Acids Res. 2017; 45: 2677-80.
10. Zhang C, Liu Z, Ding H, Miao H, Garcia MJ, Li YP. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci Rep. 2017; 7: 2273.
11. Bu LL, Yu GT, Wu L, Mao L, Deng WW, Liu JF, et al. STAT3 induces immunosuppression by upregulating PD-1/PD-1 in FINCC. J Dent Res. 2017; 96: 1027-34.
12. Austin JW, Lu P, Majumder P, Ahmed R, Ross JM. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol. 2014; 192: 4876-86.
13. Bally AP, Austin JW, Ross JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol. 2016; 196: 2431-7.
14. Kao C, Oestreicher JJ, Faley MA, Crawford A, Angelosanto JM, Ali MA, et al. Transcription factor T-bet suppresses expression of the inhibitory PD-1 receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Med. 2011; 17: 663-71.
15. Shin HM, Kapoor V, Guan T, Karch SM, Welsh RM, Berg LJ. Epigenetic modifications induced by Blimp-1 regulate CD8(+) T cell memory progression during acute virus infection. Immunity. 2013; 39: 661-75.
16. Stronon MM, Gray SM, Marshall HD, Paish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. J Immunol. 2014; 190: 8476-86.
17. Thomsen DS, Koelewer VH, Herzig P, Roller A, Trefyn M, Dimeloe S, et al. A functionally and transcriptionally distinct PD-1(Delta+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018; 24: 994-1004.
18. Li J, Van Valkenburgh B, Jurest J, Hu S, Bremner L,_PIXEL, et al. Combined blockade of IL6 and PD-1/PD-1L signaling augments mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018; 78: 5011-22.
19. Haranadhi K, Hasayhi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018; 4: 374-78.
20. Tanaka T, Okiyama N, Okane M, Ishitaka Y, Watanabe R, Furuta J, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab reactivity. J Dermatol Sci. 2017; 86: 71-73.
21. Jang J, Li Y, Zhu B. Toll-like receptor 4 in the tumor microenvironment. Cell Death Dis. 2015; 6: e1792.
22. Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Antigen presentation of tumor cells regulated by Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci Rep. 2017; 7: 2273.
23. Bally AP, Austin JW, Ross JM. Genetic and epigenetic regulation of PD-1 expression. J Immunol. 2016; 196: 2431-7.
24. Rao Y, Pan W, Pan X, Su X, Liu F, et al. The transcription factor FoxO sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. J Immunol. 2014; 190: 8476-86.
25. Kao C, Oestreicher JJ, Faley MA, Crawford A, Angelosanto JM, Ali MA, et al. Transcription factor T-bet suppresses expression of the inhibitory PD-1 receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Med. 2011; 17: 663-71.
26. Shin HM, Kapoor V, Guan T, Karch SM, Welsh RM, Berg LJ. Epigenetic modifications induced by Blimp-1 regulate CD8(+) T cell memory progression during acute virus infection. Immunity. 2013; 39: 661-75.
27. Stronon MM, Gray SM, Marshall HD, Paish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. J Immunol. 2014; 190: 8476-86.
28. Higashio H, Satoh Y, Itoh T, Hara H, Honma A, et al. IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumor immune responses in old age. Nat Commun. 2015; 6: 6702.
29. Thomsen DS, Schreiner J, Muller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells.
defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015; 3: 1344-55.
54. Damuzzo V, Solito S, Pinton L, Carrozzo E, Valpione S, Pigozzo J, et al. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology. 2016; 5: e124959.
55. Wahl RU, Leijts M, Araujo A, Rubben A. Correlative monitoring of immune activation and tissue damage in malignant melanoma-an algorithm for identification of tolerance breakage during immune checkpoint inhibitor therapy of cancer. Int J Mol Sci. 2020; 21: 2020.
56. Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020; 8: e000678.